Limit

Terra Drone, Unifly, and Aloft Technologies Launch UTM Development for AAM Targeting Global Markets

Retrieved on: 
Thursday, April 25, 2024
Air traffic service, AAM, Ecosystem, Safety, Imagination, Morgan Stanley, Research, Limit, Transport, ICAO, NOTAM, Knowledge, Automation, ViaMichelin, Robotics, UAM, Urban Air Mobility, UTM, Advanced Air Mobility, Growth

TOKYO, April 24, 2024 /PRNewswire/ -- Terra Drone Corporation, a leading drone and Advanced Air Mobility (AAM) technology provider headquartered in Japan, has announced the launch of joint development with its Group companies Unifly NV ("Unifly") and Aloft Technologies Inc. ("Aloft") focused on UAS Traffic Management (UTM) (1) for AAMs targeting global markets. Terra Drone has been making strides in its pioneering UTM business via strategic investments in Unifly, a leading UTM technology provider based in Belgium, and Aloft, which has the top UTM market share in the U.S. This collaboration marks the world's first-ever (2) joint UTM development for AAMs by multiple companies with extensive track records in UTM implementation and operation. The three companies made the announcement at the prominent uncrewed system and robotics expo XPONENTIAL 2024 in San Diego.

Key Points: 
  • TOKYO, April 24, 2024 /PRNewswire/ -- Terra Drone Corporation, a leading drone and Advanced Air Mobility (AAM) technology provider headquartered in Japan, has announced the launch of joint development with its Group companies Unifly NV ("Unifly") and Aloft Technologies Inc. ("Aloft") focused on UAS Traffic Management (UTM) (1) for AAMs targeting global markets.
  • This collaboration marks the world's first-ever (2) joint UTM development for AAMs by multiple companies with extensive track records in UTM implementation and operation.
  • Terra Drone, Unifly, and Aloft are embarking on this joint UTM development to seize the opportunities presented by the rapid global progress in electric vertical take-off and landing aircrafts (eVTOLs), which are poised to revolutionize transportation.
  • Through this groundbreaking initiative, the three companies aim to build a global UTM infrastructure that kickstarts the AAM industry worldwide.

Terra Drone, Unifly, and Aloft Launch UTM Development for AAM Targeting Global Markets

Retrieved on: 
Thursday, April 25, 2024
AAM, Ecosystem, Safety, Morgan Stanley, Research, Limit, Transport, Automation, UAM, Urban Air Mobility, UTM, Advanced Air Mobility, Growth

TOKYO, April 25, 2024 /PRNewswire/ -- Terra Drone Corporation, a leading drone and Advanced Air Mobility (AAM) technology provider headquartered in Japan, announced today the launch of joint development with its Group companies Unifly NV ("Unifly") and Aloft Technologies Inc. ("Aloft") focused on UAS Traffic Management (UTM) for AAMs targeting global markets.

Key Points: 
  • TOKYO, April 25, 2024 /PRNewswire/ -- Terra Drone Corporation, a leading drone and Advanced Air Mobility (AAM) technology provider headquartered in Japan, announced today the launch of joint development with its Group companies Unifly NV ("Unifly") and Aloft Technologies Inc. ("Aloft") focused on UAS Traffic Management (UTM) for AAMs targeting global markets.
  • Terra Drone has been making strides in its pioneering UTM business via strategic investments in Unifly, a leading UTM technology provider based in Belgium, and Aloft, which has the top UTM market share in the U.S.
  • This collaboration marks the world's first-ever joint UTM development for AAMs by multiple companies with extensive track records in UTM implementation and operation.
  • The three companies pursue joint UTM development to capitalize on the rapid global progress in electric vertical take-off and landing aircrafts (eVTOLs), set to revolutionize transportation.

ChromaCode Announces Publication Highlighting Advancements in HDPCR NSCLC Assay Performance, Demonstrating Advantages Over Next Generation Sequencing in Enabling Timely Results, and as a Vital 'Rescue' Solution when NGS is not Viable

Retrieved on: 
Tuesday, November 14, 2023
Glioma, Cholangiocarcinoma, Diagnosis, DNA, NCCN, Gene, Neoplasm, Detection, National Comprehensive Cancer Network, Non-small-cell lung cancer, Deletion, Genomics, Patient, Lung cancer, Laboratory, Biomarker, Workflow, Thyroid, Limit, NGS, Cancer, LOD, RNA, Biopsy, Vaccine, Multiplexing, NSCLC

"We are very pleased with the results of this scientific study which demonstrates the utility of the NSCLC assay as an efficient and cost-effective frontline tool to benefit lung cancer patients.

Key Points: 
  • "We are very pleased with the results of this scientific study which demonstrates the utility of the NSCLC assay as an efficient and cost-effective frontline tool to benefit lung cancer patients.
  • In this newly published research, the NSCLC assay demonstrated remarkable sensitivity, even with minimal input material obtained from formalin-fixed paraffin-embedded (FFPE) tissue samples.
  • This technology addresses key challenges in NSCLC diagnosis and treatment by offering rapid biomarker testing with minimal input, making it an ideal choice for laboratories worldwide.
  • 78% of discordant results were resolved in favor of the HDPCR assay.

William P. Donnelly Appointed to Quanterix’s Board of Directors

Retrieved on: 
Monday, August 21, 2023
Neurology, Cardiology, Biometrics, Biotechnology, Oncology, Health, Infectious Diseases, Health Technology, Bachelor of Science in Information Technology, IPO, Ingersoll Rand, Partex Group, Information technology, Serum, Infection, Limit, Research, John Carroll University, Plasma, Protein, Corporation, Trustee, Blood, Mettler Toledo, Diagnosis, Growth, News, Disease, Donnelly (surname), Management, Medical imaging, Science

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it appointed William (Bill) P. Donnelly to its Board of Directors.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it appointed William (Bill) P. Donnelly to its Board of Directors.
  • Over his tenure, he strategically oversaw the company from a leveraged buy-out to an IPO and advised the company once it successfully went public.
  • Mr. Donnelly received a Bachelor of Science in business administration from John Carroll University, where he currently serves as a chairman on the Board of Trustees.
  • “I’m eager to leverage my experience to further Quanterix’s business strategy and its next stage of growth,” said Donnelly.

Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients

Retrieved on: 
Monday, July 31, 2023
Technology, Research, Neurology, Genetics, Other Technology, Other Health, Health, General Health, Science, European Medicines Agency, Professor, University, Partex Group, Blood, Spinal muscular atrophy, Lancet Neurology, AFL, Serum, Disability, Senior counsel, Parent, Person, Infection, Philip Niarchos, University Hospital of Basel, Limit, DSM-IV codes, Biomarker, Multiple sclerosis, Teaching hospital, Plasma, TEM Toloue-4, Protein, Patient, Data, Physician, HIV disease progression rates, Corporation, Ageing, Cardiology, University of Basel, News, The Lancet, Disease, Pharmaceutical industry, Medical imaging, Nursing

The Blood Neurofilament Light Chain (NfL) is an innovative biomarker that specifically indicates neuroaxonal health.

Key Points: 
  • The Blood Neurofilament Light Chain (NfL) is an innovative biomarker that specifically indicates neuroaxonal health.
  • However, its clinical application has been constrained due to the lack of established reference ranges for children and adolescents.
  • Accurate monitoring of neuroaxonal injury in neurologic and systemic diseases is of pivotal importance at population and individual patient levels.
  • “Measurement of serum NfL concentrations has the potential to substantially contribute to counseling of children and their parents and adolescents with neurological conditions, representing a significant driver of pediatric disability concerns worldwide.

From Surviving to Thriving: One of the Oldest Audio Blogs ProRec Makes a Comeback

Retrieved on: 
Friday, May 19, 2023
Internet, DAW, Music, Name, Limit, Blog, ProRec, Cassette tape

One of the oldest and most well-recognized audio sites on the Internet, ProRec, has revived once again under the leadership of its new owner, Talal Khan.

Key Points: 
  • One of the oldest and most well-recognized audio sites on the Internet, ProRec, has revived once again under the leadership of its new owner, Talal Khan.
  • Launched in 1998 by Rip Rowan and later under Brent Randall's leadership, the site published several viral pieces, including Over the Limit .
  • Figure 1  In the realm of audio education, ProRec's audio engineers shape comprehensive, insightful audio tutorials, delivering a harmonious blend of technical expertise and pedagogical finesse.
  • ProRec has diverse technical staff comprised of audio engineers who are well-versed in all aspects of audio and have experience with a wide array of studio equipment.

Shangri-La Launches Global "Find Your Shangri-La" Campaign

Retrieved on: 
Wednesday, May 24, 2023
Taste, Perfume, Partnership, Crown Jewels of the United Kingdom, Shard, Eiffel, Ebru, Limit, Daydreamer, History, Snow, Art Basel, Rainbow, Collection, Nature, Tower, Happiness, Coffee, United Kingdom, Over the Rainbow, Eiffel Tower, Hotel, Nightclub, Frankincense, Guerlain

NEW YORK, May 24, 2023 /PRNewswire/ -- Shangri-La launches its new "Find Your Shangri-La" global campaign, created to help guests find their personal moments of joy at the luxury hotel chain renowned for its delivery of Asian hospitality.

Key Points: 
  • NEW YORK, May 24, 2023 /PRNewswire/ -- Shangri-La launches its new "Find Your Shangri-La" global campaign, created to help guests find their personal moments of joy at the luxury hotel chain renowned for its delivery of Asian hospitality.
  • "The new brand film captures the unique way in which we delight our guests with special moments and treats through our warm, authentic hospitality.
  • We are excited to debut our campaign with this film, alongside an array of immersive experiences that elevate our brand experience."
  • Shangri-La has also created a collection of imaginative cocktails and mocktails inspired by the "Find Your Shangri-La" campaign theme.

Corteva Agriscience Announces Bexoveld™ Active as Global Brand for Newest Active Ingredient from its Innovation Pipeline

Retrieved on: 
Tuesday, May 9, 2023
Farmer, Triticale, Digital, Limit, Soil, Chief digital officer, Agriculture, Kochia, Corteva

INDIANAPOLIS, May 9, 2023 /PRNewswire/ -- Corteva Agriscience today announces Bexoveld™ active as the brand name for the newest herbicide from its robust innovation pipeline.

Key Points: 
  • INDIANAPOLIS, May 9, 2023 /PRNewswire/ -- Corteva Agriscience today announces Bexoveld™ active as the brand name for the newest herbicide from its robust innovation pipeline.
  • Corteva expects to launch Bexoveld in North America in 2028 and in Europe in 2030, pending regulatory reviews.
  • "Bexoveld demonstrates Corteva Agriscience's commitment to bringing farmers innovative, sustainable, crop protection solutions," said Robert King, Executive Vice President – Crop Protection Business, Corteva Agriscience.
  • "With Bexoveld, Corteva will continue adding value to the cereal herbicide market by providing expanded spectrum weed control through differentiated products."

FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials

Retrieved on: 
Tuesday, April 25, 2023
Science, Research, General Health, Health, FDA, Technology, Genetics, Other Technology, LDT, Partex Group, Therapy, AFL, Serum, Survival, Infection, Limit, Massachusetts General Hospital, Biomarker, Multiple sclerosis, DSM-IV codes, Amyloidosis, Plasma, CLIA, Protein, Corporation, Publication, RRMS, SOD1, Patient, Laboratory, Mass, Blood, Simoa, Laboratory developed test, Neurology, Cardiology, Phase, ALS, News, Disease, Pharmaceutical industry, Medical imaging

This is the first known case in which a blood biomarker was successfully used as a surrogate endpoint for a neurology therapeutic trial to gain accelerated approval, highlighting the potential for other therapeutic trial designs to benefit from including blood NfL measurements.

Key Points: 
  • This is the first known case in which a blood biomarker was successfully used as a surrogate endpoint for a neurology therapeutic trial to gain accelerated approval, highlighting the potential for other therapeutic trial designs to benefit from including blood NfL measurements.
  • This data supported an extended FDA review of tofersen’s new drug application under the accelerated pathway leading to its recent announcement of approval.
  • The FDA’s decision to approve tofersen through its Accelerated Approval Program focused on strong surrogate biomarker data, adding momentum to the use of biomarkers in predicting disease severity and clinical benefit in neurodegenerative diseases.
  • NfL, in particular, has been extensively studied in different neurodegenerative diseases, including Alzheimer’s, spinal muscular atrophy, hereditary transthyretin-mediated amyloidosis, and multiple sclerosis.

Des Moines Art Center Hires New Director from The Met

Retrieved on: 
Tuesday, February 7, 2023
University, Fleming, Metropolitan Museum of Art, Education, Des Moines Art Center, Strategic planning, Met, Limit, Blanton Museum of Art, Princeton University Art Museum, Acquisition, Princeton University, Moses Austin, Retirement, Museum, Art Center, Woman, Knowledge, Come, Sculpture, Interior design, Art, Trustee

DES MOINES, IA (February 2023) – The Des Moines Art Center Board of Trustees has announced Dr. Kelly Baum as the museum's next John and Mary Pappajohn Director.

Key Points: 
  • DES MOINES, IA (February 2023) – The Des Moines Art Center Board of Trustees has announced Dr. Kelly Baum as the museum's next John and Mary Pappajohn Director.
  • In this role, Dr. Baum will lead the Art Center in furthering its mission to provide opportunities for transformational art experiences through its collections, exhibitions, and educational programming.
  • “The Des Moines Art Center is an exceptional place.
  • Dr. Baum will assume the role of director in May 2023 following the retirement of Jeff Fleming who has served the Art Center for 25 years.